Skip to main navigation Skip to search Skip to main content

A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

  • Allison Rosenthal
  • , Shaji Kumar
  • , Craig Hofmeister
  • , Jacob Laubach
  • , Ravi Vij
  • , Amylou Dueck
  • , Katherine Gano
  • , A. Keith Stewart

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)323-325
Number of pages3
JournalBritish Journal of Haematology
Volume174
Issue number2
DOIs
StatePublished - Jul 1 2016

Keywords

  • Alisertib
  • Aurora kinase
  • Bortezomib
  • Multiple myeloma
  • Relapse

Cite this